AI assistant
Phio Pharmaceuticals Corp. — Earnings Release 2024
Aug 14, 2024
35112_rns_2024-08-14_8d7229c7-875e-4cab-9bf6-8e6a68c3950d.zip
Earnings Release
Open in viewerOpens in your device viewer
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 14, 2024
PHIO PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36304 | 45-3215903 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 11 Apex Drive , Suite 300A, PMB 2006 | |
|---|---|
| Marlborough , Massachusetts | 01752 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: ( 508 ) 767-3861
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class: | Trading
Symbol(s): | Name
of each exchange on which registered: |
| --- | --- | --- |
| Common
Stock, par value $0.0001 per share | PHIO | The Nasdaq Capital
Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Field: Page; Sequence: 1
Field: /Page
Item 2.02. Results of Operations and Financial Condition.
On August 14, 2024, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended June 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).
The information in this Item 2.02 and attached as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Press |
| release issued by the Company on August 14, 2024. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Field: Page; Sequence: 2
2
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| /s/
Robert Bitterman |
| --- |
| Robert Bitterman President & Chief Executive Officer |
Field: Page; Sequence: 3; Options: Last
3
Field: /Page Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjVEKwjAQRE/QOyz5FhuDBemnRUWsUoqIv8GuEmyzZRO1PZK3NLaIy8KyzLwZISZiQ2tTI8N5WeZwxKattUco8YqM9oLBkW13KYRb4s04z9r64f2BGQUGA5NMldJBGKxP47BKQSaxXMRqDnKeJgqKvYi+ekb2aiq03ugatK2gYGrZoNfcjwlH3ZGlph+qTsjOkE1hNpWj/AYlZwoO9NQv4ruDPM9ENBkmEhumRxtcq86j/ZKwqrEJdW6k/xt9AAinSpA=